Moderna advances mRNA-4200 cancer therapy clinical trial

• Moderna dosed the first U.S. participant in its Phase 1 clinical trial evaluating the mRNA-4200 cancer antigen therapy.
• The company shares traded higher in the broader market following the clinical development announcement.
• The business stated the investigational treatment is designed to induce targeted T-cell responses against advanced solid tumors.

Moderna (NASDAQ:MRNA) dosed the first U.S. participant in its Phase 1 trial evaluating the mRNA-4200 cancer antigen therapy.

The clinical study evaluates the investigational treatment in adults suffering from advanced or metastatic solid tumors.

The multicenter trial tests the safety and tolerability of the new medication when administered alongside standard checkpoint inhibitor therapies.

The company stated the therapy encodes seven specific antigens designed to induce targeted T-cell responses against selected tumor targets.

The manufacturer partnered with Immatics to utilize artificial intelligence platforms for target discovery.

The administered dose at the START Mountain Region facility in Salt Lake City marks the third off-the-shelf cancer antigen therapy entering clinical development for the company.

The biotechnology business continues to expand its oncology pipeline beyond traditional vaccines to address severe medical conditions and treatment-resistant diseases.